CAJ | 학술논문

多种疾病，包括心血管疾病，被广泛认为是炎症性疾病。许多细胞因子和趋化因子参与心血管疾病的病理生理过程。绝经的本质是卵巢功能的衰竭，机体雌激素的缺乏，导致糖脂代谢异常，炎症因子失衡，机体处于慢性炎症状态。单核细胞趋化蛋白1（monocyte chemoattractant protein-1，MCP-1）可诱导、调节其他炎性因子的形成和释放，形成级联反应，介导炎症反应，因此MCP-1被认为是炎症反应的启动因子。MCP-1趋化单核细胞在内皮下聚集，转变成泡沫细胞，导致脂肪纹及动脉粥样硬化斑块的形成，被认为是动脉粥样硬化的关键因子。有研究表明，绝经激素治疗（menopause hormone therapy，MHT）可下调绝经女性血清MCP-1水平，从而发挥心血管保护作用。综述MCP-1与MHT的研究现况，特别是MCP-1与MHT的心血管保护作用研究进展。
다충질병，포괄심혈관질병，피엄범인위시염증성질병。허다세포인자화추화인자삼여심혈관질병적병리생리과정。절경적본질시란소공능적쇠갈，궤체자격소적결핍，도치당지대사이상，염증인자실형，궤체처우만성염증상태。단핵세포추화단백1（monocyte chemoattractant protein-1，MCP-1）가유도、조절기타염성인자적형성화석방，형성급련반응，개도염증반응，인차MCP-1피인위시염증반응적계동인자。MCP-1추화단핵세포재내피하취집，전변성포말세포，도치지방문급동맥죽양경화반괴적형성，피인위시동맥죽양경화적관건인자。유연구표명，절경격소치료（menopause hormone therapy，MHT）가하조절경녀성혈청MCP-1수평，종이발휘심혈관보호작용。종술MCP-1여MHT적연구현황，특별시MCP-1여MHT적심혈관보호작용연구진전。
A variety of diseases, including cardiovascular disease, are widely recognized as inflammatory diseases. Many cytokines and chemokines are involved in the pathological processes of cardiovascular disease. Menopause is estrogen′s deficiency, which leads to the glucolipid metabolic abnormality, inflammatory factors′ imbalance, the state of chronic inflammation. Monocyte chemoattractant protein-1 (MCP-1) induces and regulates the formation and release of other inflammatory cytokines, mediating inflammation, therefore is considered as the start of the inflammatory factor. MCP-1 chemokines monocyte from the lumen to the subendothelial space, initiating foam cells and fatty streak formation that leads to atherosclerotic plaque formation, which is considered to be the key factor of atherosclerosis. Research has shown that menopause hormone therapy (MHT) can down regulate the level of postmenopausal women serum MCP-1,so as to exert its effect of cardiovascular protection. MCP-1 and the cardiovascular protective effect of MHT will be summarized.